Cipla has signed a licensing agreement with Novartis Pharma AG to manufacture and market the Galvus range, used for treating type 2 diabetes, starting January 1, 2026. The deal is expected to strengthen Cipla’s position as a top player in India’s diabetes category. Subject to certain conditions, the Mumbai-based company will produce and market Galvus and Galvus combination brands on a perpetual basis. Galvus is a leading brand in the Dipeptidyl Peptidase-4 (DPP4) space and a prominent oral diabetic medication.